MXPA05010707A - Combinaciones que comprenden farmacos anti-epilepticos para el tratamiento de desordenes neurologicos. - Google Patents
Combinaciones que comprenden farmacos anti-epilepticos para el tratamiento de desordenes neurologicos.Info
- Publication number
- MXPA05010707A MXPA05010707A MXPA05010707A MXPA05010707A MXPA05010707A MX PA05010707 A MXPA05010707 A MX PA05010707A MX PA05010707 A MXPA05010707 A MX PA05010707A MX PA05010707 A MXPA05010707 A MX PA05010707A MX PA05010707 A MXPA05010707 A MX PA05010707A
- Authority
- MX
- Mexico
- Prior art keywords
- combinations
- treatment
- neurological disorders
- epileptic drugs
- epileptic
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 208000025966 Neurological disease Diseases 0.000 title abstract 2
- 239000001961 anticonvulsive agent Substances 0.000 title abstract 2
- 230000003556 anti-epileptic effect Effects 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0307860.7A GB0307860D0 (en) | 2003-04-04 | 2003-04-04 | Organic compounds |
| PCT/EP2004/003518 WO2004087161A1 (en) | 2003-04-04 | 2004-04-02 | Combinations comprising anti-epileptic drugs for the treatment of neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05010707A true MXPA05010707A (es) | 2005-12-12 |
Family
ID=9956223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05010707A MXPA05010707A (es) | 2003-04-04 | 2004-04-02 | Combinaciones que comprenden farmacos anti-epilepticos para el tratamiento de desordenes neurologicos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20060194766A1 (enExample) |
| EP (1) | EP1620103A1 (enExample) |
| JP (1) | JP2006522062A (enExample) |
| CN (1) | CN100546581C (enExample) |
| AU (1) | AU2004226825B2 (enExample) |
| BR (1) | BRPI0409170A (enExample) |
| CA (1) | CA2521274A1 (enExample) |
| GB (1) | GB0307860D0 (enExample) |
| MX (1) | MXPA05010707A (enExample) |
| WO (1) | WO2004087161A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| EP2164489A2 (en) * | 2007-07-13 | 2010-03-24 | Eisai R&D Management Co., Ltd. | Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain |
| WO2009015244A1 (en) * | 2007-07-23 | 2009-01-29 | Synosia Therapeutics | Rufinamide for the treatment of post-traumatic stress disorder |
| PL3061821T3 (pl) | 2009-07-22 | 2020-01-31 | PureTech Health LLC | Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| CN112789042A (zh) | 2018-09-28 | 2021-05-11 | 卡鲁娜治疗学有限公司 | 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB864536A (en) * | 1957-11-06 | 1961-04-06 | Sapos S A Lab | ª‡-ethyl-phenylacetylurea |
| GB1028234A (en) * | 1964-01-06 | 1966-05-04 | Ici Ltd | New pharmaceutical compositions comprising 5-aminodibenzocycloheptene derivatives |
| WO1989005642A1 (en) * | 1987-12-22 | 1989-06-29 | Ferkany John W | Dextrorphan potentiator for anticonvulsant composition and method |
| US5095033A (en) * | 1991-03-01 | 1992-03-10 | Laboratoires Biocodex | Method for treating epilepsy |
| IT1261808B (it) * | 1993-07-06 | 1996-06-03 | Impiego di l-carnitina o acido l-carnitine e valproato nel trattamentodei disosrdini convulsivi | |
| WO1998017692A1 (en) * | 1996-10-19 | 1998-04-30 | University Of Wales, Bangor | Preparation of chemically reactive polysaccharides |
| TR199900897T2 (xx) * | 1996-10-24 | 1999-07-21 | Novartis Ag | Ornat�lm�� aminoalkanfosfonik asitler. |
| US6306909B1 (en) * | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
| CN1265889A (zh) * | 1999-03-06 | 2000-09-13 | 王学勇 | 一种治疗癫痫病的药物 |
| IL149530A0 (en) * | 1999-12-01 | 2002-11-10 | Ucb Sa | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders |
| US6191117B1 (en) * | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
| KR20050044396A (ko) * | 2001-11-12 | 2005-05-12 | 노파르티스 아게 | 정동 및 주의력 장애 및 신경병성 통증 치료용 의약제조에 사용하기 위한 모노히드록시카르바마제핀 |
-
2003
- 2003-04-04 GB GBGB0307860.7A patent/GB0307860D0/en not_active Ceased
-
2004
- 2004-04-02 CN CNB2004800092188A patent/CN100546581C/zh not_active Expired - Fee Related
- 2004-04-02 CA CA002521274A patent/CA2521274A1/en not_active Abandoned
- 2004-04-02 EP EP04725366A patent/EP1620103A1/en not_active Withdrawn
- 2004-04-02 WO PCT/EP2004/003518 patent/WO2004087161A1/en not_active Ceased
- 2004-04-02 MX MXPA05010707A patent/MXPA05010707A/es not_active Application Discontinuation
- 2004-04-02 AU AU2004226825A patent/AU2004226825B2/en not_active Ceased
- 2004-04-02 JP JP2006504970A patent/JP2006522062A/ja active Pending
- 2004-04-02 BR BRPI0409170-1A patent/BRPI0409170A/pt not_active IP Right Cessation
- 2004-04-02 US US10/550,381 patent/US20060194766A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004226825B2 (en) | 2007-08-16 |
| BRPI0409170A (pt) | 2006-04-11 |
| WO2004087161A1 (en) | 2004-10-14 |
| CA2521274A1 (en) | 2004-10-14 |
| JP2006522062A (ja) | 2006-09-28 |
| GB0307860D0 (en) | 2003-05-14 |
| AU2004226825A1 (en) | 2004-10-14 |
| EP1620103A1 (en) | 2006-02-01 |
| US20060194766A1 (en) | 2006-08-31 |
| CN100546581C (zh) | 2009-10-07 |
| CN1767832A (zh) | 2006-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY127290A (en) | New use of flibanserin | |
| EP1558220A4 (en) | ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES | |
| WO2005002515A3 (en) | Delivery of therapeutic compounds to the brain and other tissues | |
| SG166820A1 (en) | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders | |
| SE0303571D0 (sv) | Medical product for moisture-sensitive medicaments | |
| WO2004043341A3 (en) | Treatment for hemorrhagic shock | |
| MXPA05012358A (es) | Combinacion farmaceutica que comprende modafinilo y otra droga. | |
| WO2004087880A3 (en) | Compounds and their use to treat diabetes and related disorders | |
| IL157226A0 (en) | Composition and method for potentiating drugs | |
| WO2004073615A8 (en) | Deazaflavin compounds and methods of use thereof | |
| MXPA05010707A (es) | Combinaciones que comprenden farmacos anti-epilepticos para el tratamiento de desordenes neurologicos. | |
| TW200628473A (en) | Novel heterocycles | |
| BG108452A (en) | Tablet comprising cetirizine and pseudoephedrine | |
| WO2005004854A3 (fr) | Utilisation de la betaine pour le traitement des arterites | |
| WO2005092062A3 (en) | Compounds for neurodegenerative disorders | |
| IL168308A (en) | Compositions containing roflumilast and formoterol | |
| UA90504C2 (ru) | Лекарственное средство для лечения заболеваний дыхательных путей | |
| WO2005081972A3 (en) | Maleiimide anti-tumor phosphatase inhibitors | |
| MXPA05007253A (es) | Sales novedosas de derivados anticonvulsivantes. | |
| WO2005020904A3 (en) | Oral neurotherapeutic cefazolin compositions | |
| UA83017C2 (uk) | Комбінація рофлуміласту та r,r-формотеролу для лікування захворювань дихальних шляхів | |
| WO2008014232A3 (en) | Pharmaceutical formulations for the treatment of alzheimer's disease | |
| MXPA05003844A (es) | Compuestos con base de glucosa con afinidad para p-selectina. | |
| MXPA03010919A (es) | Uso de acetil l-carnitina para preparacion de medicamento para terapia preventiva del dolor. | |
| WO2003059394A3 (fr) | Compositions pour la vectorisation d'oligonucleotides a travers la barriere hematoencephalique et leur utilisatin pour le traitement des maladies du systeme nerveux central |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |